Product Description
Mechanisms of Action: Protein Hydrolyzer
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Canada | Chile | Egypt | India | Ireland | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Spain | Switzerland | Taiwan | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Healthgen Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Pleurisy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HY1005-2023-2-P1 | P1 |
Not yet recruiting |
Pleurisy |
2025-07-01 |